AbbVie’s PD-1 x VEGF agreement with RemeGen was the first-quarter’s biggest.
ApexOnco Front Page
Recent articles
The latest Chinese pivotal study of iza-bren will be in first-line small-cell lung cancer.
The company discontinues one of its two KRAS G12D degraders.
After a phase 3 push the livmoniplimab plan falters.
A phase 3 trial is downgraded, and the second line now looks like the main focus for turmetabart adizutecan.
With a slashed valuation the newly listed biotech heads for phase 3.
SGN-CEACAM5C carries the same antibody as the discontinued tusamitamab ravtansine.
An actinium-based backup and Werner helicase inhibitor are notable absences.
